NY-BREGAL-SAGEMOUNT
10.1.2023 09:01:39 CET | Business Wire | Press release
Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, today announced a strategic growth investment in Enhesa (the “Company”), a leading provider of regulatory and sustainability intelligence worldwide. As part of the transaction, Sagemount will acquire ICG’s minority stake in Enhesa, with existing investor CGE Partners (“CGE”) retaining its majority stake in the Company. Financial terms of the transaction were not disclosed.
With its global headquarters in Brussels, Belgium and U.S. headquarters in Arlington, VA, Enhesa empowers multinational corporations worldwide to help create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions, supported by a team of over 100 in-house legal experts. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future.
“We are thrilled to be partnering with Sagemount as we enter our next stage of growth,” said Peter Schramme, CEO of Enhesa. “With their and CGE’s support and deep industry expertise, we believe we are well-positioned to further invest in our current offerings as well as accelerate new content coverage, use cases, and customer verticals.”
“We see tremendous growth ahead for Enhesa as a result of the Company’s strong product-market fit and tangible customer ROI,” said Pavan Tripathi, Partner at Sagemount. “Enhesa has an impressive track record of consistently retaining and growing its customer relationships as well as expanding new content offerings and jurisdictional coverage through both organic and inorganic growth initiatives. We are excited to be working with Peter, the Enhesa team, and CGE.”
David Greenbaum, Vice President at Sagemount, added, “For enterprises that operate, manufacture, and sell globally, Enhesa is by far the leading third-party content provider, allowing companies to monitor relevant Environmental, Health, & Safety (“EHS”) and other regulations across the enterprise significantly faster and more accurately than internal teams or disparate, regional third-party content providers.”
"We have enjoyed a highly successful partnership with Enhesa since acquiring the Company in 2020. Under CGE’s ownership to date, Enhesa has meaningfully scaled its business, expanded its industry-leading regulatory compliance content set from EHS to also include Product Compliance and Sustainability Intelligence, and completed five strategic add-on acquisitions," CGE commented. "We look forward to continuing to support Enhesa in its next chapter of growth alongside Sagemount."
Sagemount’s investment was led by Pavan Tripathi, Sandeep Swaminathan, David Greenbaum, Harrison Boyajian, and Stephanie Li. Sagemount was advised by Raymond James and Goodwin Procter. Enhesa and CGE were advised by Houlihan Lokey and Travers Smith.
About Enhesa
Enhesa is the leading provider of regulatory and sustainability intelligence worldwide. Headquartered in Brussels, with offices in Washington, DC, Williamsport, PA, Toronto, the United Kingdom, Tokyo, Shanghai, and Portugal, Enhesa empowers multinational corporations worldwide to create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future. For more information on Enhesa, go to the firm's website at www.enhesa.com.
About Sagemount
Bregal Sagemount is a leading growth-focused private capital firm with more than $6.0 billion of capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 70 companies in a variety of sectors, including software, information / data services, financial technology & specialty finance, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York, Palo Alto, and Dallas. For more information, visit the Sagemount website: www.sagemount.com or follow us on LinkedIn.
About CGE
CGE Partners is a European mid-market investment fund. CGE invests in tech-enabled businesses facilitating the transition to a more digital, renewable, secure, and compliant future, providing capital and expertise to accelerate expansion in global markets. For more information, visit the CGE website: https://cge-partners.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom